Tina Vilsbøll

Tina Vilsbøll

Clinical Professor

Member of:

  • Internal Medicine: Endocrinology


  1. 2008
  2. Published

    Patient-reported rating of gastrointestinal adverse effects during treatment of type 2 diabetes with the once-daily human GLP-1 analogue, liraglutide

    Horowitz, M., Vilsbøll, Tina, Zdravkovic, M., Hammer, M. & Madsbad, Sten, 1 Jul 2008, In: Diabetes, Obesity and Metabolism. 10, 7, p. 593-6 4 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Published

    Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus

    Vilsbøll, Tina, Brock, B., Perrild, H., Levin, K., Lervang, H., Kølendorf, K. E., Krarup, T., Schmitz, O., Zdravkovic, M., Le Thi Thanh, X. & Madsbad, Sten, 1 Feb 2008, In: Diabetic Medicine. 25, 2, p. 152-6 5 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus

    Vilsbøll, Tina & Knop, Filip Krag, 1 Jan 2008, In: BioDrugs. 22, 4, p. 251-7 7 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Published

    Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

    Højberg, P. V., Vilsbøll, Tina, Rabøl, R., Knop, Filip Krag, Bache, M., Krarup, T., Holst, Jens Juul & Madsbad, Sten, 2008, In: Diabetologia. 52, 2, p. 199-207 9 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  6. Published

    Glucagon-like peptide-1, glucose homeostasis and diabetes.

    Holst, Jens Juul, Deacon, Carolyn F., Vilsbøll, Tina, Krarup, T. & Madsbad, Sten, 2008, In: Trends in Molecular Medicine. 14, 4, p. 161-8 8 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  7. Published

    Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: Challenges and feasibility

    Knop, F. K., Holst, Jens Juul & Vilsbøll, Tina, 2008, In: IDrugs. The Investigational Drugs Journal. 11, 7, p. 497-501 4 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  8. Published

    The incretin system and its role in type 2 diabetes mellitus

    Holst, Jens Juul, Vilsbøll, Tina & Deacon, Carolyn F., 2008, In: Molecular and Cellular Endocrinology. 297, 1-2, p. 127-136 10 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  9. 2007
  10. Published

    Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes

    Vilsbøll, Tina, Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J., Verhoeven, R., Bugánová, I. & Madsbad, Sten, 1 Jun 2007, In: Diabetes Care. 30, 6, p. 1608-10 3 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  11. Published

    Betydningen af inkretinhormonerne glucose-dependent insulinotropic peptide og glucagon-like peptide-1 for patogenesen ved type 2-diabetes mellitus

    Vilsbøll, Tina & Knop, Filip Krag, 28 May 2007, In: Ugeskrift for Laeger. 169, 22, p. 2101-5 5 p.

    Research output: Contribution to journalJournal articleResearchpeer-review

  12. Published

    Glucagon-like peptide 1-baseret behandling af type 2-diabetes mellitus

    Knop, Filip Krag & Vilsbøll, Tina, 28 May 2007, In: Ugeskrift for Laeger. 169, 22, p. 2095-9 5 p.

    Research output: Contribution to journalReviewResearchpeer-review

ID: 33056950